WO1997040165B1 - Nouveaux produits de construction d'adn de cytomegalovirus humain, et leurs utilisations - Google Patents

Nouveaux produits de construction d'adn de cytomegalovirus humain, et leurs utilisations

Info

Publication number
WO1997040165B1
WO1997040165B1 PCT/US1997/006866 US9706866W WO9740165B1 WO 1997040165 B1 WO1997040165 B1 WO 1997040165B1 US 9706866 W US9706866 W US 9706866W WO 9740165 B1 WO9740165 B1 WO 9740165B1
Authority
WO
WIPO (PCT)
Prior art keywords
immunogenic composition
pδrc
group
hcmv
human cytomegalovirus
Prior art date
Application number
PCT/US1997/006866
Other languages
English (en)
Other versions
WO1997040165A9 (fr
WO1997040165A1 (fr
Filing date
Publication date
Application filed filed Critical
Priority to US09/171,699 priority Critical patent/US6448389B1/en
Priority to AU28098/97A priority patent/AU2809897A/en
Priority to EP97922429A priority patent/EP0914441A2/fr
Publication of WO1997040165A1 publication Critical patent/WO1997040165A1/fr
Publication of WO1997040165B1 publication Critical patent/WO1997040165B1/fr
Publication of WO1997040165A9 publication Critical patent/WO1997040165A9/fr

Links

Abstract

L'invention concerne des molécules d'ADN nouvelles servant à exprimer in vitro et in vivo le complexe gB du cytomégalovirus humain et des dérivés du complexe gB dont la transmembrane a été supprimée, tels que les protéines pp65, pp150 et IE-exon-4. Ces molécules sont de préférence des plasmides. L'invention concerne également des procédés d'utilisation de ces molécules d'ADN de façon à induire des réponses immunitaires en réaction au cytomégalovirus humain, et l'utilisation d'un plasmide de la présente invention, qui sert à amorcer des réponses immunitaires lors de l'administration de vaccins contre le cytomégalovirus humain.
PCT/US1997/006866 1996-04-23 1997-04-22 Nouveaux produits de construction d'adn de cytomegalovirus humain, et leurs utilisations WO1997040165A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US09/171,699 US6448389B1 (en) 1996-04-23 1997-04-22 Human cytomegalovirus DNA constructs and uses therefor
AU28098/97A AU2809897A (en) 1996-04-23 1997-04-22 Novel human cytomegalovirus dna constructs and uses therefor
EP97922429A EP0914441A2 (fr) 1996-04-23 1997-04-22 Nouveaux produits de construction d'adn de cytomegalovirus humain, et leurs utilisations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1571796P 1996-04-23 1996-04-23
US60/015,717 1996-04-23

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/171,699 A-371-Of-International US6448389B1 (en) 1996-04-23 1997-04-22 Human cytomegalovirus DNA constructs and uses therefor
US10/223,538 Division US20030120060A1 (en) 1996-04-23 2002-08-19 Human cytomegalovirus DNA constructs and uses therefor

Publications (3)

Publication Number Publication Date
WO1997040165A1 WO1997040165A1 (fr) 1997-10-30
WO1997040165B1 true WO1997040165B1 (fr) 1998-01-08
WO1997040165A9 WO1997040165A9 (fr) 1998-02-12

Family

ID=21773167

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/006866 WO1997040165A1 (fr) 1996-04-23 1997-04-22 Nouveaux produits de construction d'adn de cytomegalovirus humain, et leurs utilisations

Country Status (4)

Country Link
US (2) US6448389B1 (fr)
EP (1) EP0914441A2 (fr)
AU (1) AU2809897A (fr)
WO (1) WO1997040165A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040165A1 (fr) 1996-04-23 1997-10-30 The Wistar Institute Of Anatomy And Biology Nouveaux produits de construction d'adn de cytomegalovirus humain, et leurs utilisations
JP2000516617A (ja) 1996-08-14 2000-12-12 ザ・ウイスター・インステイテユート・オブ・アナトミー・アンド・バイオロジー アテローム性動脈硬化病変の出現を予防するか又は遅らせるための方法及び組成物
US6562345B1 (en) 1996-11-12 2003-05-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
US20030039657A1 (en) * 1999-04-15 2003-02-27 Johnston Stephen Albert Inducible vaccines
EP1612217A3 (fr) * 2000-03-27 2006-01-18 City of Hope Epitopes ctl peptidiques immunoréactifs du cytomégalovirus
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
AU2001271998A1 (en) 2000-07-13 2002-01-30 The Johns Hopkins University School Of Medicine Detection and treatment of polycystic kidney disease
WO2002020811A2 (fr) * 2000-09-09 2002-03-14 Basf Plant Science Gmbh Systeme inductible tet modifie permettant la regulation de l'expression genique dans des plantes
CA2425202C (fr) 2000-10-20 2012-01-03 City Of Hope Epitopes ctl peptidiques immunoreactifs du cytomegalovirus pp150
CA2460269C (fr) * 2001-09-06 2013-01-15 Alphavax, Inc. Systemes de vecteurs a base de replicons alphaviraux
SI2311848T1 (sl) 2002-12-23 2013-11-29 Vical Incorporated Cepiva proti okuĹľbi humanega citomegalovirusa z optimizacijo kodona, ki temeljijo na polinukleotidu
US7494805B2 (en) * 2003-02-14 2009-02-24 Biogen Idec Ma Inc. Expression cassette and vector for transient or stable expression of exogenous molecules
US20040228842A1 (en) * 2003-02-27 2004-11-18 Shan Lu Compositions and methods for cytomegalovirus treatment
KR101518309B1 (ko) * 2003-03-20 2015-05-08 알파벡스, 인크. 개선된 알파바이러스 레플리콘 및 헬퍼 구축물
AU2004257214B2 (en) * 2003-07-11 2010-04-22 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
US20080044384A1 (en) * 2004-06-25 2008-02-21 Medlmmune Vaccines, Inc. Recombinant Human Cytomegalovirus And Vaccines Comprising Heterologous Antigens
US7850977B2 (en) * 2007-06-21 2010-12-14 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
CN102123732A (zh) 2008-06-20 2011-07-13 杜克大学 用于引发免疫应答的组合物，方法及试剂盒
US8812387B1 (en) 2013-03-14 2014-08-19 Csidentity Corporation System and method for identifying related credit inquiries
WO2015048744A2 (fr) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucléotides codant des polypeptides de modulation immunitaire
JP6679484B2 (ja) * 2013-12-11 2020-04-15 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド ヒトヘルペスウイルス三量体糖タンパク質Ｂ、三量体ｇＢを含むタンパク質複合体、及びワクチンとしてのそれらの使用
WO2017070613A1 (fr) 2015-10-22 2017-04-27 Modernatx, Inc. Vaccin contre le cytomégalovirus humain
RU2616245C2 (ru) * 2015-12-29 2017-04-13 Сейфаддин Гашим Оглы Марданлы Композиция для профилактики заболеваний, вызываемых цитомегаловирусной инфекцией
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
JP6980780B2 (ja) 2016-10-21 2021-12-15 モデルナティーエックス， インコーポレイテッド ヒトサイトメガロウイルスワクチン
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959466A (en) 1974-04-15 1976-05-25 The Wistar Institute Highly attenuated cytomegalovirus vaccine and production thereof
ZA858044B (en) 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US4689225A (en) 1984-11-02 1987-08-25 Institut Merieux Vaccine for cytomegalovirus
CA1335429C (fr) 1986-03-07 1995-05-02 Geoffrey L. Smith Procedes de fabrication de glycoproteines hcmv, les anticorps et les vaccins diriges contre ces glycoproteines hcmv, et leurs vecteurs recombinants
DE3619720A1 (de) 1986-06-12 1987-12-17 Behringwerke Ag Hauptglykoprotein des menschlichen cytomegalovirus, seine herstellung und verwendung
ES2044881T3 (es) * 1986-06-12 1994-01-16 Behringwerke Ag Procedimiento para la preparacion de una fosfoproteina estructural (pp 150) del citomegalovirus humano.
DE3619902A1 (de) 1986-06-13 1988-03-03 Biotechnolog Forschung Gmbh Cmv-dna-strukturen, expressionsvektor dafuer, cmv-proteinstrukturen und deren verwendung
ZA878031B (en) 1986-11-04 1988-04-28 Scripps Clinic And Research Foundation Nucleic acid probes for the detection of latent human cytomegalovirus in blood products
US5153311A (en) 1986-11-24 1992-10-06 The Children's Hospital, Incorporated Immunogenic glycoproteins of human cytomegalovirus gCII
US5124440A (en) 1986-11-24 1992-06-23 The Childrens Hospital, Inc. Antibody and T cell recognition sites on glycoproteins comprising the GCI complex of human cytomegalovirus
EP0277773A1 (fr) 1987-01-30 1988-08-10 The Board Of Trustees Of The Leland Stanford Junior University Cytomégalovirus hybride et vaccin
AU641121B2 (en) 1988-01-29 1993-09-16 Chiron Corporation Recombinant CMV neutralizing proteins
WO1990000062A1 (fr) 1988-07-01 1990-01-11 The Children's Hospital, Incorporated Reconnaissance de fragments provenant de cytomegalovirus a l'aide d'anticorps
WO1990006771A1 (fr) 1988-12-12 1990-06-28 The Children's Hospital, Incorporated Fragments proteolytiques obtenus a partir du complexe i de glycoproteines de cytomegalovirus humain
US5552143A (en) 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
EP0389286B1 (fr) 1989-03-24 1996-07-10 The Wistar Institute Of Anatomy And Biology Vaccin recombinant contre le virus cytomégalo
WO1991002004A1 (fr) 1989-08-07 1991-02-21 Children's Biomedical Research Center GLYCOPROTEINES IMMUNOGENIQUES DU CYTOMEGALOVIRUS HUMAIN gCII
AU7906691A (en) 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
GB9014652D0 (en) 1990-07-02 1990-08-22 Wellcome Found Antigen
WO1992002628A1 (fr) 1990-08-02 1992-02-20 Chiron Corporation Expression de glycoproteine-h de cytomegalovirus humain utilisant le systeme d'expression cellulaire de baculovirus-insectes
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
WO1994017810A1 (fr) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Vaccin recombine contre le cytomegalovirus
CA2160583A1 (fr) 1993-04-16 1994-10-27 Stanley A. Plotkin Vaccin de type cytomegalovirus recombinant
IT1266740B1 (it) 1994-07-01 1997-01-14 Maria Paola Landini Materiale proteico ricombinante legante anticorpi contro il citomegalovirus umano, reagenti diagnostici derivati da tale
WO1997040165A1 (fr) 1996-04-23 1997-10-30 The Wistar Institute Of Anatomy And Biology Nouveaux produits de construction d'adn de cytomegalovirus humain, et leurs utilisations

Similar Documents

Publication Publication Date Title
WO1997040165B1 (fr) Nouveaux produits de construction d'adn de cytomegalovirus humain, et leurs utilisations
Prehaud et al. Immunogenic and protective properties of rabies virus glycoprotein expressed by baculovirus vectors
Osterrieder et al. Protection against EHV-1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB)
EP0139417B1 (fr) Vaccins à base de protéines liées à des membranes et procédé pour leur préparation
Yoo et al. The S2 subunit of the spike glycoprotein of bovine coronavirus mediates membrane fusion in insect cells
CA2228221A1 (fr) Produits de recombinaison de polyproteine de papillomavirus
Konishi et al. A vipox virus-vectored Japanese encephalitis virus vaccines: use as vaccine candidates in combination with purified subunit immunogens
CA2054069A1 (fr) Systeme d'expression
JP2005333990A (ja) ｇｐ３５０／２２０非スプライシング変異体
Sarkar et al. Polypeptides of the mouse mammary tumor virus: II. Identification of two major glycoproteins with the viral structure
EP0538341B1 (fr) Vaccin a base de glycoproteine de vhe-4 (virus d'herpes equin-4)
CA2275340A1 (fr) Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin
EP0117657A1 (fr) Polypeptides immunogènes contre la rage et vaccin utilisant ces peptides, séquences d'ADN, vecteurs d'expression, cellules recombinantes, cultures et procédés pour leur production
Meindl et al. The equine herpesvirus 1 Us2 homolog encodes a nonessential membrane-associated virion component
ALLEN et al. Role of coexpression of IL-2 and herpes simplex virus proteins in recombinant vaccinia virus vectors on levels of induced immunity
EP0913157B1 (fr) Vaccin composite contenant un antigene, un anticorps et un adn recombinant et son procede de preparation
JP2852395B2 (ja) ネコ白血病ウイルスワクチン
Frenchick et al. Biochemical and immunological characterization of a novel peptide carrier system using rotavirus VP6 particles
WO1997003187A3 (fr) Genes du virus de la maladie de marek et leur utilisation dans des vaccins qui protegent contre la maladie de marek
EP0471457A2 (fr) Vecteur herpesviral exprimant un épitope du virus de la fièvre aphteuse
Harty et al. Characterization of the myristylated polypeptide encoded by the UL1 gene that is conserved in the genome of defective interfering particles of equine herpesvirus 1
KR100768051B1 (ko) 간염 바이러스 ｏｒｆ2의 ｎ-말단 영역으로부터 유래한프로세싱 성분 및 항원성 폴리펩티드를 암호화하는 핵산구성물
Osterrieder et al. Deletion of gene 52 encoding glycoprotein M of equine herpesvirus type 1 strain RacH results in increased immunogenicity
Perez-Hernandez et al. Expression and characterization of the gD protein of HSV-2 fused to the tetramerization domain of the transcription factor p53
JP2759035B2 (ja) 単純ヘルペスウイルス感染防御用ワクチン